Almost a year and a half after DBV Technologies pulled its peanut allergy immunotherapy patch from FDA review, the biotech will get their day in court. The FDA has scheduled an ...
It was all going so well. Last week, Teva investors saw the light at the end of the tunnel, after Israel's largest drugmaker handsomely beat Wall Street sales expectations by $100 million ...
